ArticleHealth science reports2025
Lineage and Sublineage Analysis of Human Papillomavirus Types 66 and 68 in Iran During 2021-2023: A Cross-Sectional Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Knowing the distribution of HPV lineages and sublineages can provide more information on this virus's epidemiology, evolution, and pathogenicity. The present study intends to investigate the sequence variations of the E6 gene to know the distribution of lineages and sublineages of HPV 66 and 68 types in Iran. Methods: Seventy-one HPV 66 and 59 HPV 68-positive samples were investigated to identify their lineage/sublineages by hemi-nested PCR and sequencing. Results: Most of the HPV 66-infected samples belonged to lineage B (77.5%) and the remaining (22.5%) were classified as lineage A. For sublineage classification, 22.5%, 12.7%, and 64.8% were sublineages A1, B1, and B2, respectively. Most of the HPV 68-positive samples were classified as lineage C (66.1%), followed by lineage A (25.4%), lineage D/E (6.8%), and lineage F (1.7%). According to detected sublineages, C1 was dominant (62.7%), followed by A1 (22%), D/E (6.8%), A2 (3.4%), C2 (3.4%), and F2 (1.7%). No statistically significant differences were observed concerning HPV 66 or 68 distinct lineages by histology/cytology status. Conclusion: Our results showed that the B2 sublineage of HPV 66 and the C1 sublineage of HPV 68 were dominant in Iranian women. However, to elucidate the role of HPV 66 and 68 lineages in the pathogenicity risk of these two types, more studies with larger sample sizes are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.